| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |